Goldman Sachs analysts led by Steven Kron share the firm's latest conviction list, which includes 23 of the bank's top picks ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Fintel reports that on June 6, 2025, Goldman Sachs upgraded their outlook for MasTec (NYSE:MTZ) from Neutral to Buy. Analyst ...

Fintel reports that on June 6, 2025, Goldman Sachs downgraded their outlook for MYR Group (NasdaqGS:MYRG) from Buy to Neutral ...

Goldman Sachs BDC in its Q1'25 reported an improved balance sheet, new dividend flexibility, 17% NAV discount, and rebound ...

Goldman Sachs suggests hedging with gold and positioning for dollar weakness against major currencies. Markets have turned ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Goldman Sachs has added these three stocks to its Conviction List. They all have at least 20% upside potential to the analyst ...

Elon Musk has alienated “multiple sides of the political spectrum” from Tesla, according to one prominent Wall Street analyst ...

Goldman Sachs analysts said they see alternatives to protect portfolios from volatility as bonds and stocks often sell off in ...